The role of PD-L1 expression as a predictive biomarker in advanced
non-small-cell lung cancer:
a network
meta-analysis
Systematic Review Aguiar Jr, Santoro, Tadokoro
et al.
Immunotherapy
(2016) 8(4), 479–488
• 13 trials with a total.
• 1979 patients included in the current analysis
• PD-L1 positive---652 patients.
•
PD-L1 negative---915 patients.
•
RR –13% in PD-L1-negative
